Navigation Links
New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting

-limiting toxicity (DLT) was evaluated based on the first cycle of treatment and DLT was not reached in 21 patients who received the combination regimen including patients who received the full FDA approved doses of each agent. Further, all patients' platelet and neutrophil counts recovered to protocol defined levels and times allowing for re-treatment after cycle one. At baseline, median Gleason Score was eight, median PSA values were 162 ng/ml and 43% of patients had previously received taxane-based chemotherapy. Following treatment, 12 out of 21 patients achieved a 50% or greater decline in PSA. Data on progression-free survival are pending.

The authors concluded that repetitive dosing of QUADRAMET and docetaxel was feasible and well-tolerated. Clinically significant hematologic toxicity was rare and does not appear to be related to dose or disease burden. Plans are underway for a multi-center Phase 2 study with Memorial Sloan-Kettering Cancer Center and other leading prostate cancer centers.

"With bone pain representing a significant quality-of-life concern for patients with metastatic prostate cancer, we wanted to see if we could combine QUADRAMET, an FDA-approved drug to treat bone pain, with docetaxel, an FDA-approved drug to treat late stage prostate cancer, and administer both at their respective, FDA-approved therapeutic doses without compromising patient safety," explained Michael J. Morris, M.D., an oncologist specializing in prostate cancer at Memorial Sloan-Kettering Cancer Center. "The Phase 1 data demonstrate that repeated doses of QUADRAMET are safe and do not appear to impair the effective delivery of docetaxel in most patients."

"Phase 1 trial with combination of docetaxel (D) plus samarium-13 (Sm 153) in patients (pts) with hormone refractory prostate cancer (HRPC)" by Sinibaldi et al. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD (Abstract No. 15547, published in the ASCO proceedings)

Simil
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
2. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
7. VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
8. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
9. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
10. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Data for Cytogen QUADRAMET Reported Annual ASCO Meeting
(Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
(Date:8/27/2015)... YORK , August 27, 2015 ... published by Persistence Market Research titled "Global Market ... Witness Highest Growth by 2021", the urinary catheters market is ... the end of 2015. It is anticipated to ... 2021, to reach US$1,755.0 Mn by 2021. ...
(Date:8/27/2015)... 2015  QB3@953—a San Francisco ... California (UC) research institute and biotech accelerator— today ... identify and facilitate collaborations to translate early drug ... The agreement formalizes a relationship between QB3@953 ... and creates a new channel for DPAc to ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Berger Health System, recognized as one of the ... to AutoCarousel® HD by Talyst, a leader of pharmacy ... has a built-to-last 10 years guarantee. Berger ... is also implementing AutoPharm®, AutoPack™ and AutoLabel® to help ...
... Lineagen, Inc., an innovative molecular diagnostics company focused on ... nonprofit subsidiary of the National Multiple Sclerosis Society, today ... validation of a blood-based assay for multiple sclerosis (MS). ... test that can aid clinicians in diagnosing MS, distinguishing ...
Cached Medicine Technology:Berger Health System Partners With Pharmacy Automation Leader to Improve Patient Safety 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 3Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 4
(Date:8/27/2015)... ... August 27, 2015 , ... Cytovance® Biologics, ... biopharmaceutical contract development manufacturing company (CDMO), announced today that it has entered into ... in cash. , The addition of Cytovance Biologics to Hepalink USA ...
(Date:8/27/2015)... ... 27, 2015 , ... Susan Harris and the team at LifeStream ... to pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch ... to the vaginal tissue, revitalizing cells so they make more collagen, an essential component ...
(Date:8/27/2015)... Rocky Hill, CT (PRWEB) , ... August 27, 2015 , ... ... Portal Companies List. , “The companies selected have the platforms required not only to ... training,” said Ken Taylor, President of Training Industry, Inc. , For six consecutive ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... firm that helps libraries, publishers and companies leverage key operational, technical, business ... the VIVO Project. Gunter Media Group, Inc., will provide VIVO related services ...
(Date:8/27/2015)... Newport Beach, CA (PRWEB) , ... August 27, ... ... services and products, announced today that the new issue of Chairside® magazine, its ... the latest issue, Volume 10, Issue 3, as well as past issues of ...
Breaking Medicine News(10 mins):Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 2Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 3Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 3
... , , BATESVILLE, Ind., and ... today announced a strategic partnership agreement to integrate the Radianse ... system. With this move, Hill-Rom intends to extend its ... financial and technical obstacles for health care customers as they ...
... NOVATO, Calif., Sept. 2 BioMarin Pharmaceutical Inc. (Nasdaq: ... Chief Financial Officer of BioMarin, will present a company update at the ... at 4:25 p.m. ET. , , Interested ... the investor section of the BioMarin website, www.BMRN.com . ...
... SOMERSET, N.J., Sept. 2 Meda Pharmaceuticals ... (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for ... rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% ... for patients who suffer from seasonal allergies. ASTEPRO Nasal Spray ...
... /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; "the Company") announced ... publicized the creation of "Opinions of the,CPC Central Committee and ... Health Care System" ("Opinion"). , The ... a,doctor more easily. Reduced cost is the short-term goal and ...
... , , , , ... Mass., Sept. 2 /PRNewswire-FirstCall/ -- ... company that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and ... Bob Doman, President and Chief Executive Officer, will present a corporate ...
... , , , ... , a medical device company, today announced that its ... the U.S. Food and Drug Administration (FDA) for the direct delivery ... may be in the treatment of cancer. , , ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:BioMarin to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 2Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 3Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: